Detailed answers about PRIMUS CLINICAL RESEARCH CONSULTANTS LIMITED, including incorporation, status, business activity, and accounts information.
When was PRIMUS CLINICAL RESEARCH CONSULTANTS LIMITED founded?
PRIMUS CLINICAL RESEARCH CONSULTANTS LIMITED was officially incorporated on 5 April 2016 and is registered under company number 10104968. Incorporation establishes the company as a legal entity registered at Companies House, allowing it to trade, enter contracts, and operate under UK company law.
What type of company is PRIMUS CLINICAL RESEARCH CONSULTANTS LIMITED?
Private Limited Company. This classification indicates the legal structure of the company, which determines the way it is governed, its liability, and regulatory obligations. A private limited company (Ltd) limits the personal liability of its shareholders.
What is the current status of PRIMUS CLINICAL RESEARCH CONSULTANTS LIMITED?
PRIMUS CLINICAL RESEARCH CONSULTANTS LIMITED's current status is Active. The company status indicates whether it is actively trading, dormant, or has been dissolved. Maintaining an active status is essential for legally conducting business, filing accounts, and maintaining credibility with partners and lenders.
What does PRIMUS CLINICAL RESEARCH CONSULTANTS LIMITED do?
PRIMUS CLINICAL RESEARCH CONSULTANTS LIMITED operates in the following sector: 72110 - Research and experimental development on biotechnology. This provides insight into the company's primary business activity and industry focus.
What is PRIMUS CLINICAL RESEARCH CONSULTANTS LIMITED's registered address?
The registered office address of PRIMUS CLINICAL RESEARCH CONSULTANTS LIMITED is 89 HIGH STREET, HADLEIGH, IPSWICH, SUFFOLK, UNITED KINGDOM, IP7 5EA. This is the official address filed with Companies House for legal and statutory correspondence.
Is PRIMUS CLINICAL RESEARCH CONSULTANTS LIMITED financially stable?
The most recent accounts for PRIMUS CLINICAL RESEARCH CONSULTANTS LIMITED were made up to 30 April 2025, filed as MICRO ENTITY. Next accounts are due by 31 January 2027.